on the operator curve in Figure 1 . Negative LE and nitrite alone is less specific ], Specificity 0.859 [95% CI 0.858-0.859]).
INTRODUCTION AND OBJECTIVES: Nitrofurantoin (NF) is used to treat recurrent urinary tract infections (RUTI)
. Despite minimal data, the Beers criteria has cautioned against long-term use of NF in geriatric patients. This study reviews the safety and efficacy of chronic suppressive therapy with NF in neurogenic (NG) and nonneurogenic (NN) post-menopausal women.
METHODS: A query of the electronic medical record at a tertiary care institution yielded 11,200 charts of women aged 50-95 prescribed NF by over 75 providers from 2006-2018 in outpatient clinics. Charts from primary urology providers prescribing NF therapy for at least 3 consecutive months were further analyzed. Demographics, reason for initiation of NF, dose, duration, explanation of therapy interruptions, resistance, occurrence of adverse, comorbid conditions, urine culture, and relevant lab and imaging results were recorded. Start and stop dates of chronic suppressive therapy were tallied from the medication lists and cross-referenced with documentation by the provider for accuracy. Number of months on chronic suppressive therapy were summed. RESULTS: Of the 221 patients included, 167 (77%) were prescribed 100mg of NF. The most common indication for chronic NF therapy was RUTI prophylaxis. 104 (47%) patients developed cultures resistant to NF but only 4 were switched to an alternative suppressive therapy. 88 (40%) patients developed breakthrough UTI but only 10 were not restarted on NF (4 patients due to NF resistance). NG patients had a higher occurrence of catheter use (p[0.0008) but NN patients had an increased incidence of breakthrough UTI (p[0.0134). There was no difference in resistance rates between NG and NN groups (p[0.4361). No patients developed neuropathy, 1 developed liver dysfunction after 3.5 years of therapy, and 4 developed pulmonary symptoms after a mean use of NF for 3.5 years. None who developed chronic cough had chronic changes to their x-rays CONCLUSIONS: We conclude that post-menopausal women tolerate chronic NF suppressive therapy well with minimal risk of significant adverse events. NF is a safe and effective in the management of chronic RUTI in this patient population.
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MP71-15 PREVALENCE OF RECURRENT EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) URINARY TRACT INFECTIONS (UTIS) IN PATIENTS WITHIN A UROLOGY SERVICE. INTRODUCING THE CONCEPT OF FAECAL MICROBIOTA TRANSPLANTATION (FMT) AS A TREATMENT MODALITY
INTRODUCTION AND OBJECTIVES:
Patients with an underlying urological diagnosis colonised with multidrug-resistant organisms (MDRO) such as ESBL are predisposed to recurrent UTIs. Treatment can be prolonged with higher mortality and cost compared to infection with sensitive organisms. In FMT, healthy donor stool is administered into the GI tract to restore the healthy gut microbiota. This is acknowledged as an effective treatment for recurrent Clostridium difficile infection, and now as an emerging method of eradicating MDROs. However, there are little data reporting on its therapeutic value in Urology.
METHODS: Retrospective analysis of culture positive urine isolates was obtained from 2015 to 2018 at a tertiary level service. Clinical profiling of patients under the urology service with recurrent ESBL producing isolates was performed. Four patients who had ESBL UTIs underwent FMT. Vol. 201, No. 4S, Supplement, Monday, May 6, 2019 THE JOURNAL OF UROLOGY Ò e1051
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